Malignancy and idiopathic inflammatory myopathies

North American Journal of Medical Sciences

Volumn 5, Issue 10, 2013, Pages 569-572

  Ungprasert, Patompong ^a   Bethina, Narandra K ^b   Jones, Christine H ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Idiopathic inflammatory myopathies; Malignancy; Polymyositis

Indexed keywords

AUTOANTIBODY; AUTOANTIBODY P140; AUTOANTIBODY P155; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYOSITIS; DISEASE ASSOCIATION; ECHOGRAPHY; GYNECOLOGICAL EXAMINATION; HUMAN; INCLUSION BODY MYOSITIS; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; META ANALYSIS (TOPIC); MYOSITIS; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMYOSITIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84886998574     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.120788     Document Type: Review

References (27)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis-I. New Engl J Med 1975;292:344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (Second of two parts). New Engl J Med 1975;292:403-7.
3. Stertz G, Polymyositis. Berl Klin Wochenschr 1916;53:489.
4. Manchul LA, Jin A, Pritchard KI, Tebebbaum J, Boyd NF, Lee P, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 1985;145:1835-9.
5. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-7.
6. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 1995;22:1300-3.
7. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr, et al. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.
8. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and followup implications: A Scottish population-based cohort study. Br J Cancer 2001;85:41-5.
9. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001;134:1087-95.
10. Masuda H, Urushibara M, Kihara K. Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol 2003;169:1084.
11. Yoshinaga A, Hayashi T, Ishii N, Ohna R, Watanabe T, Yamada T. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 2005;12:593-5.
12. Bonnetblanc JM, Bernard P, Fayol K. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990;180:212-6.
13. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201:591-601.
14. Zampieri S, Valente M, Adami N, Biral D, Ghirardello A, Rampudda ME, et al. Polymyositis, dermatomyositis and malignancy: A further intriguing link. Autoimmun Rev 2010;9:449-53.
15. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 2001;357:96-100.
16. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with DM/PM, and follow up implication. Br J Cancer 2001;85:41-5.
17. Antiochos B, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009;36:2704-10.
18. Ungprasert P, Leeaphorn N, Hosiriluck N, Chaiwatcharayut W, Ammannagari N, Raddatz DA. Clinical features of inflammatory myopathies and their association with malignancy: A systematic review in Asian population. ISRN Rheumatol 2013;2013:509354.
19. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 1994;73:153-60.
20. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011;13:208-15.
21. Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, et al. Dermatomyositis and polymyositis associated with malignancy: A 21-year retrospective study. J Rheumatol 2008;35:438-44.
22. Selva-O'Callaghan A, Grau-Junyent JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, et al. Conventional cancer screening versus PET/ CT in dermatomyositis/polymyositis. Am J Med 2010;123:558-62.
23. Vincent DF, Yan KP, Treilleux I, Gay F, Arfi V, Kaniewski B, et al. Inactivation of TIF1-γ cooperates with KrasG12D to induce cystic tumors of the pancreas. PLoS Genet 2009;5:e1000575.
24. Trallero-Araguas E, Rodrigo-Penda JA, Selva-O'Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of Anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and Meta-analysis. Arthritis Rheum 2012;64:523-32.
25. Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: Novel autoantibodies and new insights. Curr Opin Rheumatol 2010;22:627-32.
26. Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013;33:965-71.
27. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult onset CAMD: A missing link within the spectrum of IIM. J Am Acad Dermatol. 2006;54:597-613.